Real world use of tirzepatide in the treatment of type 2 diabetes in an Arab population

Tirzepatide was initiated in 8,945 patients with type 2 diabetes over a period of approximately 14 months.

• The mean reduction in HbA1c at 40 weeks was 0.6 ± 1.2% (8 ± 13 mmol/mol).
• Patients experienced an average weight loss of 4.5 ± 6.9 kg (4.8 ± 7.3%).
• GLP-RA-naïve patients had a greater HbA1c reduction of 1.0 ± 1.3% (11 ± 14 mmol/mol) compared to 0.5 ± 1.2% (6 ± 13 mmol/mol) in previously treated patients.
• Weight loss was also greater in GLP-RA-naïve patients, averaging 7.2 ± 8.6 kg versus 4.2 ± 6.6 kg in those previously exposed.
• Post-metabolic bariatric surgery patients lost more weight at 7.8 ± 9.4 kg compared to 4.5 ± 7.0 kg in others.
• Tirzepatide was well tolerated, with 7.8% of patients discontinuing due to adverse effects, primarily gastrointestinal.

AI simplified